Related Experiment Video
Updated: Jan 27, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators
1a Department of Obstetrics and Gynecology, Division of Midlife Health , University of Virginia Health System , Charlottesville , VA , USA.
Abstract:
Selective estrogen receptor modulators (SERMs) are synthetic non-steroidal agents which have variable estrogen agonist and antagonist activities in different target tissues. Tamoxifen is an anti-estrogen in the breast used for treatment and prevention of breast cancer, with estrogen agonist activity in the uterus. Raloxifene prevents and treats osteoporosis and prevents breast cancer, and can be safely combined with vaginal but not systemic estrogen. The tissue selective estrogen complex combines conjugated equine estrogens (CEE) with the SERM bazedoxifene (BZA). The five Selective Estrogen Menopause and Response to Therapy studies, with up to 2 years of data, demonstrated that CEE/BZA 0.45 mg/BZA 20 mg improved vasomotor symptoms and vulvovaginal atrophy, prevented bone loss, and was neutral on breast tenderness, breast density, with breast cancer incidence similar to placebo. Protection against estrogen-induced endometrial hyperplasia and cancer was found, with similar amenorrhea rates to placebo. Ospemifene is approved to treat dyspareunia, with potential benefits on bone and the breast, while lasofoxifene is being developed to treat resistant estrogen receptor-positive breast cancer in women. Estetrol is an estrogen synthesized exclusively during pregnancy by the human fetal liver and initially considered a weak estrogen, but it appears to have dual weak estrogenic/anti-estrogenic features.
Insights
Selective estrogen receptor modulators (SERMs) offer targeted benefits for women's health. Conjugated equine estrogens/bazedoxifene effectively treats menopause symptoms and prevents bone loss without increasing breast cancer risk.
Area of Science:
- Endocrinology
- Pharmacology
- Women's Health
Background:
- Selective estrogen receptor modulators (SERMs) are non-steroidal agents with tissue-specific estrogenic and anti-estrogenic effects.
- Existing SERMs like tamoxifen and raloxifene have demonstrated efficacy in breast cancer, osteoporosis, and menopausal symptom management.
- The development of novel SERMs and estrogen-based therapies aims to optimize therapeutic outcomes while minimizing adverse effects.
Purpose of the Study:
- To evaluate the efficacy and safety of a tissue-selective estrogen complex (CEE/BZA) in postmenopausal women.
- To assess the impact of CEE/BZA on vasomotor symptoms, vulvovaginal atrophy, bone mineral density, and breast health.
- To investigate the endometrial effects and safety profile of CEE/BZA compared to placebo.
Main Methods:
- The study analyzed data from the Selective Estrogen Menopause and Response to Therapy (SMART) trials.
- Participants received conjugated equine estrogens (CEE) 0.45 mg combined with bazedoxifene (BZA) 20 mg.
- Outcomes were assessed over up to two years, including symptom improvement, bone density, and breast/endometrial safety.
Main Results:
- CEE/BZA significantly improved moderate to severe vasomotor symptoms and vulvovaginal atrophy.
- The treatment effectively prevented bone loss at the lumbar spine and total hip.
- CEE/BZA demonstrated neutrality regarding breast tenderness and density, with breast cancer incidence similar to placebo. Endometrial safety was confirmed, with hyperplasia and cancer rates comparable to placebo.
Conclusions:
- The combination of conjugated equine estrogens and bazedoxifene (CEE/BZA) is an effective treatment for menopausal vasomotor symptoms and prevention of bone loss.
- CEE/BZA offers a favorable safety profile, showing no adverse effects on the breast and providing endometrial protection.
- This therapy represents a valuable option for managing menopausal symptoms and associated bone loss in postmenopausal women.
More Related Videos
09:07Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
08:02Visualization of Estrogen Receptors in Colons of Mice with TNBS-Induced Crohn's Disease using Immunofluorescence
Published on: March 12, 2020
Related Concept Videos
What is Natural Selection?
Antibiotic Selection
Types of Selection
Frequency-dependent Selection
Limits to Natural Selection
Natural Selection and Adaptation
Beyond physical adaptations,...